Baxter’s BioPharma Solutions business, a CMO that specializes in parenteral pharmaceuticals, has completed an 1,800 square meter capacity expansion designed for oncology drugs at its fill/finish contract manufacturing facility in Halle (Westfalen), Germany. The additional capacity for freeze-dried (lyophilized) cytotoxic (having a toxic effect on cells) parenterals supports growing demand for these oncology treatment programs.

The sterile manufacturing facility, which includes new equipment combined with new disinfection systems, was designed to optimize layout to improve efficiency, prevent contamination and keep potential losses on the filling line to a minimum. Extensive use of glass throughout the expansion area aims to improve visibility for workers and visitors.

“Cancer incidence continues to rise, and this completed expansion offers not only capacity but innovative processes and technologies that will allow Baxter to stay at the forefront of parenteral manufacturing for oncology therapies,” said Dr. Burkhard Wichert, vice president of manufacturing for Baxter’s BioPharma Solutions business. “We take seriously our commitment to world-class contract manufacturing of oncology products, and understand that the better we can serve our customers, the better they can serve patients around the world.”